Compugen Ltd. (NASDAQ:CGEN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Compugen Ltd. (NASDAQ:CGEN) have been assigned an average recommendation of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $5.00.

CGEN has been the topic of several research reports. Leerink Partners dropped their price objective on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, May 21st. Lake Street Capital initiated coverage on shares of Compugen in a report on Tuesday, April 7th. They set a “buy” rating and a $6.00 price objective on the stock. Truist Financial upgraded shares of Compugen to a “strong-buy” rating in a report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a report on Monday, April 20th. Finally, Wall Street Zen lowered shares of Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd.

Compugen Price Performance

CGEN stock opened at $2.04 on Monday. The firm has a market cap of $192.88 million, a price-to-earnings ratio of 5.51 and a beta of 2.74. Compugen has a 12-month low of $1.29 and a 12-month high of $3.23. The company’s fifty day simple moving average is $2.61 and its 200 day simple moving average is $2.10.

Compugen (NASDAQ:CGEN) last released its earnings results on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $2.18 million during the quarter, compared to analyst estimates of $1.57 million. Compugen had a net margin of 47.97% and a return on equity of 47.72%. Research analysts expect that Compugen will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Compugen

Institutional investors have recently made changes to their positions in the stock. Bank Hapoalim BM acquired a new position in shares of Compugen during the fourth quarter valued at about $37,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Compugen during the fourth quarter valued at about $38,000. Franklin Resources Inc. bought a new stake in shares of Compugen during the second quarter worth about $56,000. Calamos Advisors LLC bought a new stake in shares of Compugen during the first quarter worth about $63,000. Finally, Hillsdale Investment Management Inc. bought a new stake in shares of Compugen during the first quarter worth about $68,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.